



Review Article

Artificial Intelligence (AI) In Pharmaceutical Industry (PI)

S. Anupriya, N. Anvarsha, P. Kalyani*

Dept. of Chemistry, CDOE, Madurai Kamaraj University, Madurai-625021, Tamilnadu, India

Artificial intelligence (AI) is significantly transforming the pharmaceutical industry by enhancing efficiency across various stages of drug development, from discovery to introduction in market. This technology powers advanced algorithms and machine learning (ML) to analyze vast datasets, including genomic and proteomic information, allowing for the identification of disease targets and the prediction of drug interactions. As a result, AI facilitates a more targeted and efficient approach to drug discovery, potentially increasing the success rates of drug approvals while reducing development costs. Applications of AI extend to optimizing research and development processes, improving clinical trial designs, and personalizing medicine by analyzing real-world patient data. Furthermore, AI enhances quality control and operational efficiency within pharmaceutical manufacturing, contributing to the production of personalized medications tailored to individual patient needs. Despite its potential, the integration of AI in the pharmaceutical sector faces challenges, including the need for robust IT infrastructure and concerns regarding job displacement. In this paper, we indicate how the incorporation of AI in the pharmaceutical industry can present promising opportunities for innovation, efficiency, and improved patient outcomes, marking a significant shift in how drugs are developed and delivered.

Keywords: Artificial Intelligence, Pharmaceutical Industry, Drug Discovery, Personalized Medicine, Clinical Trials.

INTRODUCTION

Artificial intelligence (AI) is significantly transforming the pharmaceutical industry by enhancing efficiency across various stages of drug development, from discovery to introduction in market [1]. This technology powers advanced algorithms and machine learning to analyze vast datasets, including genomic and proteomic information, allowing for the identification of disease targets and the prediction of drug interactions [2]. Pandemics and epidemics tend to bring the healthcare industry under the limelight, and the Covid-19 pandemic was no different. In addition to logistics and civic regulations, Pharma companies have taken centre-stage during the novel Coronavirus pandemic. As a result, the pharmaceutical market has grown exponentially, and this is expected to continue in the years to come. Research indicates that the global pharmaceutical manufacturing market, valued at USD 405.52 billion in 2020, is expected to grow at a

compound annual growth rate (CAGR) of 11.34% from 2021 through 2028 [3]. Compounding the Covid-19 impact are factors like technological advancements, an increase in the number of elderly, focus on the healthcare needs of growing countries, a rise in chronic disorders, and higher spending by pharma companies on research and development [4, 5]. Naturally, every player wants to make the most of the myriad opportunities present in the market. Consequently, competition among different pharmaceutical companies has been fierce. Numerous parameters are driving this intense competition within the sector: Pharmaceutical companies, of course, have long been in the forefront of AI. Even before last year's explosion of interest, researchers were applying complex AI models to unlock the mechanisms of disease. AlphaFold2, ESMFold, and MoLeR, for example, all use deep learning to help predict the structures of nearly all known proteins,

transforming our understanding of their underlying diseases [6-8]. AI refers to the simulation of human intelligence processes by machines, especially computer systems. The integration of AI into the pharmaceutical industry is reshaping how drugs are discovered, developed, and delivered. By accelerating drug discovery, enhancing personalization, optimizing clinical trials, improving drug safety, and streamlining manufacturing, supply chain processes and brought to market, AI is driving significant advancements in pharmaceuticals. As a result, AI facilitates a more targeted and efficient approach to drug discovery, potentially increasing the success rates of drug approvals while reducing development costs [9]. AI applications extend to optimizing research and development processes, improving clinical trial designs, and personalizing medicine by analyzing real-world patient data [10, 11]. As the technology continues to evolve, it holds the promise of further revolutionizing the industry and improving patient outcomes on a global scale. Indeed, AI is transforming the pharmaceutical industry by accelerating drug discovery, enabling personalized medicine, optimizing clinical trials, improving drug safety monitoring, and enhancing manufacturing and supply chain efficiency. These advancements are helping companies reduce costs, shorten timelines, and deliver more effective treatments to patients worldwide. Therefore, this paper highlights how the

incorporation of AI in the pharmaceutical industry presents promising opportunities for innovation, efficiency, and improved patient outcomes, marking a significant shift in how drugs are developed and delivered.

1.1. Overview of AI in pharmaceuticals

AI has emerged as a transformative force across various industries, and its impact on the pharmaceutical sector is both profound and far-reaching. At its core, AI refers to the simulation of human intelligence processes by machines, particularly computer systems. In pharmaceuticals, AI encompasses a range of technologies and techniques designed to enhance drug discovery, development, manufacturing, and patient care. Recently, AI is being increasingly recognized as a transformative force in the pharmaceutical industry. From accelerating drug discovery to enabling personalized medicine, AI technologies are reshaping traditional workflows and offering new opportunities for efficiency and innovation. These applications span the entire drug development lifecycle, influencing research, clinical testing, safety monitoring, and manufacturing. To provide a clear overview of these domains, figure 1 illustrates the five major areas where AI is currently making the greatest impact on pharmaceutical practice.



Figure 1. Infographic illustrating five major domains of artificial intelligence application in the pharmaceutical industry.

1.2. AI in pharmaceuticals: The technological landscape

The pharmaceutical industry faces numerous challenges, from the lengthy and costly drug development process to the need for personalized treatments and efficient manufacturing practices. Traditional methods often struggle with the volume and complexity of data involved, leading to inefficiencies and delays. AI offers solutions by directing its capacity to analyze large datasets, recognize patterns, and make predictions. Figure 2 highlights the breadth of AI applications across the pharmaceutical value chain. AI technologies are being

deployed to improve manufacturing processes, accelerate drug discovery and design, and process complex biomedical and clinical datasets. They also enable advances in rare disease research and personalized medicine, support the identification of suitable clinical trial candidates, and enhance the prediction of treatment outcomes. In addition, AI contributes to the discovery of predictive biomarkers, facilitates drug repurposing, and strengthens adherence and dosage monitoring. Together, these applications demonstrate how AI is reshaping pharmaceutical research, development, and patient care by driving efficiency, reducing costs, and improving therapeutic precision.




Figure 2. Applications of AI in the PI.

2. Importance and impact

2.1. Accelerating drug discovery

One of the most significant impacts of AI in pharmaceuticals is its ability to accelerate drug discovery i.e. the significance of AI in pharmaceuticals lies in its potential to enhance efficiency and effectiveness across various stages of drug development. Traditionally, the process of finding new drugs is labor-intensive and time-consuming, often taking over a decade and costing billions of dollars [9]. AI can streamline this process by rapidly analyzing vast amounts of biological data, predicting which compounds are most likely to interact effectively with target proteins, and simulating clinical outcomes [12, 13]. This not only speeds up the identification of promising drug candidates but also reduces the overall cost of drug development. Thus, from identifying potential drug candidates faster to improving clinical trial processes

and personalizing treatment, AI applications are proving transformative.

2.2. Enhancing precision and personalization

The role of AI in enhancing precision and personalization in medicine is another crucial development. Personalized medicine aims to tailor treatments to individual patients based on their genetic, environmental, and lifestyle factors. AI algorithms analyze genetic data and patient records to identify biomarkers and predict how different individuals will respond to various treatments. This approach leads to more effective and targeted therapies, reducing the risk of adverse effects and improving patient outcomes.

2.3. Optimizing clinical trials

AI is revolutionizing clinical trials by improving design, patient recruitment, and data analysis. Traditionally, clinical trials are prone to delays and inefficiencies due to challenges in patient recruitment

and trial design. AI-driven tools can analyze electronic health records to identify suitable candidates more quickly and accurately [10, 14]. Additionally, AI can optimize trial designs by predicting outcomes and adjusting protocols in real-time [15, 16]. This leads to more efficient trials with higher success rates and faster time-to-market for new drugs.

2.4. Improving drug safety and pharmacovigilance

Drug safety is a critical concern in the pharmaceutical industry, and AI plays a vital role in enhancing pharmacovigilance. AI systems can analyze large volumes of data from various sources, such as electronic health records and social media, to detect adverse drug reactions and safety signals more effectively. By identifying potential safety issues early, AI helps mitigate risks and ensures that drugs are safe for public use.

2.5. Streamlining manufacturing and supply chain

AI also impacts pharmaceutical manufacturing and supply chain management. AI technologies optimize manufacturing processes by analyzing data from production lines, predicting equipment failures, and suggesting process improvements. This leads to increased efficiency, reduced operational costs, and enhanced product quality. Additionally, AI can improve supply chain management by predicting demand, managing inventory, and ensuring timely distribution of products.

2.6. Ethical and regulatory considerations

While the benefits of AI in pharmaceuticals are substantial, there are also ethical and regulatory considerations that must be addressed. Ensuring data privacy and security is paramount, particularly when dealing with sensitive patient information. Regulatory bodies are also working to establish guidelines and standards for the use of AI in drug development and healthcare. Navigating these challenges requires collaboration between AI experts, pharmaceutical companies, and regulatory agencies to ensure that AI technologies are used responsibly and effectively.

3. Historical context

3.1. Evolution of AI technologies

a. Early foundations and conceptual origins

The roots of Artificial Intelligence (AI) can be traced back to ancient myths and stories about artificial beings endowed with human-like intelligence. However, the formal study of AI began in the mid-20th century with the development of the first computers and the conceptualization of algorithms capable of simulating intelligent behavior. In 1956, the term "Artificial Intelligence" was coined at the Dartmouth Conference, a pivotal event that marked the beginning of AI as a distinct field of study. Early AI research focused on symbolic reasoning and problem-solving techniques, which laid the groundwork for future developments. These early systems, such as ELIZA and SHRDLU, demonstrated the potential of AI in natural language processing and automated reasoning.

b. Advancements in Machine Learning (ML)

The 1980s and 1990s saw significant advancements in AI, particularly with the development of Machine Learning (ML). Unlike early AI systems that relied on hard-coded rules, ML algorithms could learn from data and improve their performance over time. This shift was driven by increased computational power and the availability of larger datasets.

c. Introduction of Neural Networks and Deep Learning

The next major leap in AI came with the resurgence of neural networks in the 2000s, particularly with the advent of Deep Learning. Deep Learning involves training artificial neural networks with multiple layers (deep neural networks) to recognize patterns and make predictions. This approach was inspired by the structure and function of the human brain and proved to be highly effective in tasks such as image and speech recognition.

d. AI in pharmaceuticals: Early applications

In the early 2000s, AI began making its way into the pharmaceutical industry. Initial applications focused on data mining and predictive modeling, aiming to streamline drug discovery and development processes. Early AI systems were used to analyze

chemical structures, identify potential drug targets, and predict drug interactions. However, the potential of AI in pharmaceuticals was still limited by computational constraints and the availability of high-quality data.

e. Rise of big data and advanced AI techniques

The rise of big data and advanced computing technologies in the 2010s revolutionized AI applications in pharmaceuticals. The availability of vast amounts of biological and clinical data, combined with powerful computing resources, enabled more sophisticated AI techniques. Machine Learning and Deep Learning models could now handle complex datasets, leading to significant improvements in drug discovery, clinical trials, and personalized medicine.

4. Milestones in pharmaceutical AI

a. Early drug discovery innovations

One of the earliest and most notable milestones in pharmaceutical AI was the development of predictive modeling tools for drug discovery. In the early 2000s, companies like IBM and Pfizer began exploring AI to analyze chemical databases [17, 18] and predict the efficacy of drug candidates. These early tools used machine learning algorithms to identify potential drug candidates and predict their interactions with biological targets.

b. Breakthroughs in computational drug design

A major breakthrough came with the application of computational drug design and virtual screening. In 2012, researchers at the University of Toronto and

IBM demonstrated the use of AI to predict the binding affinity of small molecules to target proteins [19]. This milestone significantly accelerated the drug discovery process by allowing researchers to screen thousands of compounds *in silico* before conducting wet-lab experiments.

c. AI-driven drug discovery platforms

The mid-2010s marked the emergence of AI-driven drug discovery platforms. Companies such as Benevolent AI, Atomwise, and DeepMind developed AI systems capable of analyzing large-scale biological data to identify new drug candidates [6, 20, 21]. For example, Atomwise's AI platform uses deep learning algorithms to predict the binding of molecules to target proteins, leading to the discovery of new compounds for diseases like Ebola and cancer [22]. As shown in figure 3, AI is being applied across multiple stages of drug discovery and development, with leading companies employing machine-learning approaches to aggregate data, elucidate disease mechanisms, and generate novel therapeutic candidates. The infographic is organized into three domains: **aggregating and synthesizing information, understanding disease mechanisms, and generating novel drug candidates**. Within each domain, leading companies are highlighted along with their specific AI approaches—for example, Arpeggio Bio's RNA sequencing with machine learning, Phenomic AI's genome-wide analysis, Structura Biotechnology's cryo-EM modeling, Atomwise's deep CNN predictions, TwoXAR's compound library screening, and ReviveMed's metabolite mass analysis. The figure also indicates technology readiness levels (TRLs), showing the maturity of these applications.



Figure 3. Overview of AI applications in drug discovery and development, illustrating how leading companies employ machine-learning and data-driven approaches to aggregate information, understand disease mechanisms, and generate novel drug candidates across different technology-readiness levels.

d. Personalized medicine and genomic data

The impact of AI on personalized medicine became more pronounced with the integration of genomic data. In 2017, the launch of initiatives like the All of Us Research Program in the United States aimed to collect genomic and health data from diverse populations to improve personalized treatments [23]. AI algorithms analyzed this data to identify genetic markers associated with various diseases and predict individual responses to treatments. Figure 4 illustrates the process of personalized medicine through the integration and analysis of diverse patient data. On the

left, multiple data sources are represented, including phenotype, genomic, lifestyle, and gene expression information, supported by inputs such as DNA sequencing, RNA sequencing, lab tests, patient history, and imaging. These inputs converge into a high-dimensional dataset, which is then processed using learning methods and data analysis/visualization tools. The flow culminates in the development of personalized medicine, symbolized by a pill and a human figure, emphasizing how computational approaches transform raw biological and lifestyle data into individualized treatments.




Figure 4. Workflow of AI-driven personalized medicine showing how patient phenotype, genomic, lifestyle, and gene expression data are integrated into high-dimensional datasets, analyzed through computational learning methods, and translated into individualized therapeutic strategies.

e. Advancements in clinical trials

The role of AI in optimizing clinical trials became a significant milestone in the late 2010s. AI-driven tools improved patient recruitment by analyzing electronic health records and identifying suitable candidates based on specific criteria. Companies like Medidata and IBM Watson Health developed AI platforms to enhance trial design and monitoring, resulting in more efficient and effective clinical trials.

f. AI in drug safety and pharmacovigilance

In recent years, AI has made strides in drug safety and pharmacovigilance. The development of AI systems for real-time monitoring and adverse event prediction has improved drug safety profiles. For instance, IBM Watson for Drug Discovery employs AI to analyze patient data and identify potential safety concerns, helping pharmaceutical companies address issues before drugs reach the market [14,18].

g. Integration with healthcare systems

The integration of AI with healthcare systems represents a critical milestone in the 2020s. AI technologies are now embedded in electronic health records (EHRs) and healthcare platforms, enabling real-time analysis of patient data and personalized treatment recommendations. This integration enhances the overall efficiency of the pharmaceutical industry and improves patient outcomes by providing actionable insights and predictive analytics.

5. AI technologies and techniques

5.1. Machine Learning and Deep Learning

Machine Learning (ML) involves algorithms that allow computers to learn from and make predictions based on data. Deep Learning, a subset of ML, uses neural networks with multiple layers to model complex patterns. These techniques are used to analyze vast datasets, identify potential drug candidates, and predict drug efficacy.

5.2. Natural Language Processing

Natural Language Processing (NLP) enables AI to understand and interpret human language. In

pharmaceuticals, NLP is used to analyze scientific literature, extract relevant information from clinical records, and support drug discovery by identifying new research trends.

5.3. Computer Vision

Computer Vision, which enables AI to interpret and analyze visual data, is utilized in pharmaceuticals for tasks such as analyzing medical images and optimizing manufacturing processes. For instance, computer vision can detect anomalies in drug tablets or identify issues in packaging, ensuring product quality and safety.

6. Drug discovery and development

6.1. Predictive modeling

Predictive modeling involves using statistical techniques and algorithms to forecast future outcomes. In drug discovery, AI models predict which drug compounds are likely to be effective based on historical data and simulations.

6.2. Virtual screening

Virtual Screening uses computational methods to evaluate the potential of drug candidates by simulating their interactions with target proteins. AI enhances virtual screening by improving accuracy and speed, thus identifying promising candidates more efficiently.

6.3. Structure-based drug design

AI-driven structure-based drug design involves modeling the three-dimensional structure of target proteins to design molecules that can interact with them. This approach accelerates the drug discovery process and improves the likelihood of successful outcomes.

7. Preclinical and clinical trials

7.1. Patient recruitment and stratification

AI enhances patient recruitment by analyzing electronic health records and other data sources to identify suitable candidates for clinical trials. It also aids in patient stratification, ensuring that trials are

conducted with the most appropriate patient populations.

7.2. Trial design and optimization

AI algorithms can optimize trial designs by predicting outcomes, adjusting protocols in real-time, and ensuring more efficient use of resources. This leads to more robust and reliable trial results.

7.3. Data analysis and monitoring

AI tools analyze trial data to identify trends, monitor patient responses, and detect any anomalies. This real-time analysis improves the accuracy of results and helps in making timely adjustments to trial protocols.

8. Personalized medicine

8.1. Genomics and AI

AI integrates with genomics to analyze genetic data and identify biomarkers associated with specific diseases. This integration supports the development of personalized treatment plans tailored to individual genetic profiles.

8.2. Tailored treatment plans

AI systems create personalized treatment plans by analyzing patient data, including genetics, lifestyle, and medical history. This approach ensures that treatments are tailored to individual needs, improving therapeutic effectiveness and minimizing adverse effects.

8.3. Precision oncology

In oncology, AI helps in precision medicine by analyzing genetic mutations, predicting cancer progression, and recommending targeted therapies [11, 24]. This personalized approach improves treatment outcomes and reduces unnecessary interventions.

9. Pharmacovigilance and drug safety

9.1. Adverse Event Prediction

AI models predict adverse drug reactions by analyzing historical data and identifying patterns that

may indicate potential safety issues. This proactive approach helps in minimizing risks associated with drug therapies.

9.2. Real-time monitoring

AI systems enable real-time monitoring of drug safety by analyzing data from various sources, including electronic health records and social media. This continuous surveillance helps in early detection of safety concerns.

9.3. Signal detection

Signal detection involves identifying potential safety signals from large datasets. AI algorithms enhance signal detection capabilities by processing vast amounts of data and identifying patterns that may indicate emerging safety issues.

10. Manufacturing and supply chain

10.1. Process optimization

AI optimizes manufacturing processes by analyzing data from production lines, predicting equipment failures, and suggesting improvements. This leads to increased efficiency and reduced operational costs.

10.2. Quality control

AI-powered quality control systems inspect products for defects and deviations from quality standards. These systems use computer vision and machine learning to ensure consistent product quality.

10.3. Predictive maintenance

Predictive maintenance uses AI to predict when equipment is likely to fail based on historical data and real-time monitoring. This approach minimizes downtime and extends the lifespan of manufacturing equipment.

11. Regulatory and ethical considerations

11.1. Compliance and standards

AI applications in pharmaceuticals must adhere to regulatory standards and guidelines. Ensuring compliance involves working with regulatory bodies

to validate AI systems and ensure they meet safety and efficacy requirements.

11.2. Ethical implications of AI

The use of AI in pharmaceuticals raises ethical concerns, including issues related to data privacy, consent, and potential biases in AI algorithms. Addressing these concerns is crucial to ensure ethical use of AI technologies.

11.3. Data privacy concerns

Data privacy is a major concern when dealing with sensitive patient information. AI systems must incorporate robust security measures to protect data and comply with regulations such as GDPR and HIPAA.

12. Case studies

12.1. Successful AI implementations

Case studies of successful AI implementations include AI-driven drug discovery platforms, such as those developed by companies like DeepMind and Atomwise, which have led to significant breakthroughs in drug development.

12.2. Lessons learnt from failures

Analyzing failed AI projects provides insights into the challenges and pitfalls of AI in pharmaceuticals. Understanding these lessons helps in refining AI strategies and improving future implementations.

13. Future trends and developments

13.1. Emerging technologies

Emerging technologies in AI, such as quantum computing and advanced neural networks, are expected to further revolutionize the pharmaceutical industry. These technologies promise to enhance AI capabilities and expand its applications.

14. Future challenges and opportunities

The future of AI in pharmaceuticals presents both challenges and opportunities. Addressing issues such as data quality, algorithm transparency, and ethical

considerations will be crucial for realizing the full potential of AI. There are numerous questions regarding AI in pharma industry. Let us probe the probable questions and explanations. Here are a few questions.

a. How is AI transforming drug discovery in the pharmaceutical industry

Artificial intelligence (AI) is revolutionizing drug discovery in the pharmaceutical industry by enhancing efficiency, reducing costs, and accelerating timelines. Here are the key ways AI is transforming this sector:

1. Accelerated Target Identification: AI algorithms analyze extensive datasets, including genomic and clinical data, to identify potential drug targets more rapidly than traditional methods. This includes predicting the 3D structures of proteins, which aids in designing drugs that effectively interact with these targets.

2. *In Silico* Screening: AI enables virtual screening of compounds, allowing researchers to simulate how potential drugs will perform without the need for extensive physical testing. This significantly cuts down the time and resources required for initial drug evaluations.

3. Optimized Clinical Trials: AI streamlines the clinical trial process by identifying suitable candidates and predicting outcomes based on historical data. This capability enhances patient recruitment and trial design, ultimately leading to faster and more efficient trials.

4. Enhanced Drug Repurposing: AI tools can analyze existing drugs to identify new therapeutic uses, expediting the process of finding treatments for diseases without starting from scratch.

5. Improved Drug Design: Generative AI models assist in designing novel compounds by predicting their interactions with biological targets. This approach has led to the development of new drug candidates that are now entering clinical trials.

6. Cost Reduction and Increased Success Rates: By automating various stages of drug discovery and

development, AI has the potential to lower the overall costs associated with bringing a drug to market and increase the likelihood of success in clinical trials, addressing the high failure rates traditionally seen in drug development.

Thus, AI is not just a tool but a transformative force in the pharmaceutical industry, reshaping how drugs are discovered, developed, and brought to market, with the promise of making the process faster, cheaper, and more effective.

b. How does AI help in identifying potential drug targets

AI plays a crucial role in identifying potential drug targets in the pharmaceutical industry through several advanced methodologies:

1. **Data analysis and integration:** AI algorithms can analyze large and complex datasets, including genomic, proteomic, and clinical data, to uncover relationships between biological molecules and diseases. This capability allows researchers to identify potential drug targets by recognizing patterns and correlations that might be missed using traditional methods.

2. **Deep learning models:** Deep learning techniques are employed to model biological networks, which helps in understanding the interactions between various cellular components. These models can predict which biomolecules are likely to be effective targets for new drugs, especially in complex diseases like cancer.

3. **Synthetic data generation:** Generative AI can create synthetic biological data that aids in target identification. This approach allows for the exploration of novel targets and enhances the validation of AI-identified targets through experimental methods.

4. **Network-based approaches:** AI leverages network biology to analyze the interactions within cellular systems. By using graph-based neural networks, AI can predict drug-target interactions more effectively, considering both the structural properties of drugs and their biological targets.

5. **Novelty vs. confidence trade-off:** AI helps balance the selection of novel targets with those that have high confidence based on existing data. This balance is crucial for increasing the chances of success in drug development, as it allows researchers to explore innovative targets while relying on validated information.

6. **Accelerated discovery process:** By automating the target identification process, AI significantly reduces the time and resources required to discover new drug targets. This acceleration is vital in the fast-paced pharmaceutical landscape, where timely development can lead to competitive advantages.

Thus, the ability of AI to analyze vast amounts of data, model complex biological interactions, and generate new hypotheses positions it as a transformative tool in the identification of potential drug targets, ultimately enhancing the drug discovery process.

c. Some examples of AI-identified drug targets that have entered clinical trials

Several AI-identified drug targets have progressed to clinical trials in recent years, signalling the growing impact of AI in drug discovery:

- GS-0976, a drug for non-alcoholic steatohepatitis [25], identified using AI

- EXS-21546 for solid tumors, identified using AI

- INS018_055 for idiopathic pulmonary fibrosis, the first AI-derived drug to show positive topline results in a Phase 1 trial.

While AI has accelerated the identification of potential drug targets, the success of AI-discovered drugs in clinical trials remains to be seen. Some AI-derived drugs for conditions like atopic dermatitis, schizophrenia, and cancer did not meet expectations in recent trials. Challenges remain in translating AI-identified targets into clinically effective drugs. Striking the right balance between choosing high-confidence targets and novel, first-in-class targets is crucial. Continued validation of AI-identified targets through experiments and clinical trials will be important for demonstrating the real-world impact of this technology in drug discovery.

d. The main challenges of implementing AI in pharmaceutical manufacturing

Implementing AI in pharmaceutical manufacturing presents several significant challenges:

1. **Data availability and quality:** AI systems rely heavily on large datasets to learn and make accurate predictions. However, the pharmaceutical industry often faces issues with limited data availability due to the rarity of certain diseases, leading to smaller datasets that may not provide sufficient insights for AI algorithms to function effectively.

2. **Complexity of data:** The data involved in pharmaceutical manufacturing is often complex and varied, encompassing structured and unstructured formats, including clinical data, imaging, and genetic information. This complexity makes it challenging to integrate and analyze data effectively, which is crucial for AI applications.

3. **Regulatory compliance:** The pharmaceutical industry is highly regulated, requiring strict adherence to guidelines and protocols. This regulatory environment can slow down the implementation of AI technologies, as companies must ensure that AI systems comply with all necessary regulations and standards.

4. **Data security and privacy:** With the increasing reliance on digital data, concerns regarding data security and patient privacy have escalated. Cybersecurity threats pose a significant risk, and pharmaceutical companies must implement robust measures to protect sensitive information while using AI systems.

5. **Integration with existing systems:** Many pharmaceutical companies operate with legacy systems that may not be compatible with modern AI technologies. Integrating AI solutions into these existing infrastructures can be challenging and may require significant investment in new technologies and training.

6. **Skill gaps and expertise:** There is a shortage of professionals with the necessary skills to implement and manage AI technologies in the pharmaceutical sector. This skill gap can hinder the effective deployment of AI solutions, as specialized knowledge is required to interpret AI outputs and integrate them into manufacturing processes.

7. **Bias and interpretability:** AI models can be susceptible to biases based on the data they are trained on, which may lead to skewed results. Additionally, the "black box" nature of some AI algorithms makes it difficult for stakeholders to understand how decisions are made, raising concerns about transparency and accountability.

Addressing these challenges is crucial for pharmaceutical companies to fully leverage the benefits of AI in manufacturing, ultimately leading to improved efficiency, reduced costs, and enhanced product quality. Figure 5 highlights the diverse applications of AI in industrial and manufacturing processes. Four domains are illustrated:

- **Process design and scale-up:** AI models accelerate identification of optimal parameters and reduce waste during scale-up.
- **Advanced process control:** AI integrates with real-time sensor data to predict process progression and maintain stability.
- **Process monitoring and fault detection:** AI continuously monitors equipment and product quality, detecting deviations early to trigger maintenance or corrective actions.
- **Trend monitoring:** AI analyzes consumer complaints and deviation reports to identify recurring issues and guide continuous improvement.

Together, these applications demonstrate how AI enhances efficiency, reliability, and adaptability in complex industrial systems.




Figure 5. Applications of artificial intelligence in industrial and manufacturing processes, including process design and scale-up, advanced process control, monitoring and fault detection, and trend analysis for continuous improvement.

e. How does AI contribute to reducing development costs in the pharmaceutical industry?

AI contributes to reducing development costs in the pharmaceutical industry through several key mechanisms:

1. Accelerated drug discovery: AI significantly speeds up the drug discovery process by analyzing vast datasets and identifying potential candidates more quickly than traditional methods. Research indicates that AI can reduce the time taken to screen new drugs by 40% to 50%, which directly translates to lower costs associated with lengthy research timelines [9].
2. Enhanced data integration and analysis: AI tools streamline the integration of complex data from various sources, allowing for more efficient analysis. This capability helps pharmaceutical companies identify inefficiencies and redundancies in their workflows, optimizing processes and reducing waste.
3. Predictive analytics: By leveraging historical data, AI can predict potential pitfalls in clinical trial designs and outcomes. This predictive capability allows companies to make informed decisions early in the development process, potentially avoiding costly failures later on. For example, AI can identify the most promising drug candidates based on their molecular properties and historical success rates in similar trials.
4. Improved clinical trial efficiency: AI enhances the design and management of clinical trials, which are among the most expensive phases of drug development. AI systems can optimize patient recruitment, monitor trial progress, and analyze results more efficiently, thereby reducing the overall costs associated with clinical trials.
5. Automation of routine tasks: AI can automate many manual and low-level cognitive tasks involved in drug development, allowing researchers to focus on more complex and strategic activities. This automation not only speeds up the development process but also reduces labor costs associated with repetitive tasks.
6. Cost savings across the R&D lifecycle: The McKinsey Global Institute estimates that AI applications in the pharmaceutical sector could save nearly \$100 billion annually by improving efficiencies across the entire research and development lifecycle. These savings stem from reduced time to market and increased success rates in drug development.

By integrating AI into various stages of drug development, pharmaceutical companies can achieve

significant cost reductions, improve efficiency, and ultimately bring new therapies to market more rapidly.

f. What role does machine learning play in predicting drug toxicity?

Machine learning (ML) plays a pivotal role in predicting drug toxicity, significantly enhancing the drug development process by providing accurate and efficient methods for assessing the safety of new compounds. Here are the key contributions of ML in this area:

1. Data-driven predictions: ML algorithms excel at analyzing large datasets to identify patterns and correlations that indicate potential toxicity. By leveraging historical toxicity data and molecular descriptors, ML models can predict the harmful effects of compounds before they undergo costly and time-consuming clinical trials.

2. Reduction of animal testing: Traditional toxicity testing methods often involve extensive animal studies, which raise ethical concerns and can be time-consuming. ML models can reduce the reliance on these methods by providing *in silico* predictions, thereby addressing both ethical issues and development timelines.

3. Enhanced accuracy and efficiency: ML techniques, such as support vector machines, random forests, and deep learning, have demonstrated superior performance in predicting various toxicity endpoints, including hepatotoxicity, cardiotoxicity, and mutagenicity. These models can achieve high accuracy, sensitivity, and specificity, which are crucial for identifying potentially toxic compounds early in the drug development process.

4. Integration of diverse data sources: ML models can integrate various types of data, including chemical structures, biological activity, and pharmacokinetic properties, to provide a more holistic view of the safety profile of a compound. This comprehensive approach allows for better predictions and a deeper understanding of the mechanisms underlying toxicity.

5. Continuous learning and improvement: As more data becomes available, ML models can be

continuously updated and refined, improving their predictive capabilities over time. This adaptability is essential in a rapidly evolving field like drug discovery, where new compounds and data are constantly emerging.

6. Cost and time efficiency: By streamlining the toxicity prediction process, ML can significantly reduce the costs associated with drug development. It allows researchers to filter out compounds with high toxicity risk early in the pipeline, thereby focusing resources on the most promising candidates and minimizing late-stage failures.

To summarize, machine learning enhances drug toxicity prediction by providing accurate, efficient, and ethical alternatives to traditional methods, ultimately leading to safer drugs and more streamlined development processes.

g. How can AI improve personalized medicine approaches?

AI significantly enhances personalized medicine approaches by leveraging vast amounts of patient data to tailor treatments to individual needs. Here are the primary ways AI contributes to this transformation:

1. Data integration and analysis: AI technologies can process and analyze diverse data types, including genomic, proteomic, clinical, and lifestyle information. This integration allows for a comprehensive understanding of a patient's unique health profile, enabling more accurate diagnoses and treatment plans tailored to individual characteristics.

2. Predictive analytics: Machine learning algorithms can identify patterns and predict how different patients will respond to specific treatments. By analyzing historical data, AI can help healthcare providers anticipate patient outcomes and select the most effective interventions, thus improving treatment efficacy.

3. Identification of biomarkers: AI can assist in discovering new biomarkers that indicate how a patient might respond to a particular therapy. This capability is crucial for developing targeted therapies that are more effective and have fewer side effects, as

treatments can be aligned with the biological makeup of the patients.

4. Enhanced preventive care: AI can analyze genetic predispositions and lifestyle factors to identify individuals at higher risk for certain diseases. This early detection allows for proactive interventions and personalized preventive strategies, ultimately improving overall health outcomes.

5. Clinical decision support: AI systems provide healthcare professionals with decision support tools that enhance clinical judgment. By offering evidence-based recommendations based on specific data of the patient, AI helps clinicians make informed decisions about treatment options, leading to better patient care.

6. Continuous learning and improvement: AI systems can learn from new data and clinical outcomes, refining their algorithms over time. This continuous improvement enhances the precision of personalized medicine approaches, ensuring that treatment recommendations evolve with emerging evidence and patient experiences [26].

7. Cost reduction: By optimizing treatment plans and improving patient outcomes, AI can help lower healthcare costs associated with ineffective treatments and hospitalizations. Personalized medicine approaches powered by AI can lead to more efficient use of resources and better allocation of healthcare services.

To summarize, the ability of AI to analyze complex datasets, predict individual responses, and support clinical decision-making is revolutionizing personalized medicine, making healthcare more effective and tailored to the unique needs of each patient.

h. What role does AI play in integrating genomic data into personalized medicine?

AI plays a transformative role in integrating genomic data into personalized medicine by enhancing the analysis and interpretation of complex genetic information. Here are the key contributions of AI in this integration:

1. Efficient data processing: AI algorithms can process vast amounts of genomic data quickly and accurately. This capability is crucial given the complexity and volume of data generated by high-throughput sequencing technologies. By analyzing this data, AI helps identify genetic variations and mutations linked to diseases, enabling more precise diagnoses and treatment strategies.

2. Pattern recognition: Machine learning models excel at recognizing patterns within genomic data that may not be apparent through traditional analysis. These patterns can indicate predispositions to certain diseases or responses to specific treatments, allowing healthcare providers to tailor interventions based on the genetic profile of an individual.

3. Predictive analytics: AI can predict how patients will respond to various therapies based on their genomic makeup. This predictive capability allows clinicians to select the most effective treatment options while minimizing adverse effects, thus enhancing patient outcomes.

4. Discovery of biomarkers: AI aids in the identification of new biomarkers associated with specific diseases or treatment responses. By analyzing genomic data alongside clinical outcomes, AI can help discover genetic markers that inform targeted therapies, particularly in oncology and other complex diseases.

5. Integration with other data types: AI facilitates the integration of genomic data with other health information, such as electronic health records (EHRs), lifestyle factors, and environmental data. This holistic approach provides a comprehensive view of a patient's health, enabling more personalized and effective treatment plans.

6. Support for clinical decision-making: AI-driven tools provide healthcare professionals with insights derived from genomic data, supporting clinical decision-making. These tools can generate recommendations for treatment based on an analysis of similar cases, improving the accuracy and effectiveness of care.

7. Continuous learning: AI systems can continuously learn from new data, improving their predictive

accuracy over time. This adaptability is essential in the rapidly evolving field of genomics, where new discoveries frequently emerge.

To summarize, AI enhances the integration of genomic data into personalized medicine by enabling efficient data processing, pattern recognition, predictive analytics, and the discovery of biomarkers. These advancements lead to more tailored treatment approaches, ultimately improving patient care and outcomes.

i. How does AI-driven genomic analysis contribute to early disease detection

AI-driven genomic analysis significantly contributes to early disease detection through several key mechanisms:

1. High-throughput data processing: AI algorithms excel at processing large volumes of genomic data generated by high-throughput sequencing technologies. This capability allows for rapid analysis of genetic information, facilitating the identification of mutations and variants associated with diseases at an early stage.

2. Pattern recognition: Machine learning models can identify complex patterns within genomic data that may indicate predispositions to specific diseases. By analyzing genetic variations and their correlations with clinical outcomes, AI can help predict the likelihood of disease development before symptoms appear.

3. Biomarker discovery: AI enhances the discovery of biomarkers linked to early disease stages. By analyzing genomic data alongside clinical data, AI can identify genetic markers that signal the onset of diseases, enabling earlier and more accurate diagnoses.

4. Phenotype-to-Genotype mapping: AI systems improve the mapping of phenotypic data (observable traits) to genotypic data (genetic makeup). This mapping allows for the identification of genetic variants that contribute to specific disease phenotypes, enhancing the ability to detect diseases early based on genetic predispositions.

5. Integration of multi-omics data: AI can integrate genomic data with other omics data (like proteomics and metabolomics) and electronic health records (EHRs). This comprehensive approach provides a more holistic view of a patient's health, facilitating the early detection of diseases by considering multiple biological factors and their interactions.

6. Predictive modeling: AI-driven predictive models can assess an individual's risk of developing certain diseases based on their genomic data. These models can guide proactive measures, such as lifestyle changes or preventive treatments, thereby improving early intervention strategies.

To summarize, AI-driven genomic analysis enhances early disease detection by enabling efficient data processing, identifying genetic patterns, discovering biomarkers, and integrating diverse data sources. These advancements lead to more timely and accurate diagnoses, ultimately improving patient outcomes. While AI is being applied across diverse stages of pharmaceutical development, its contributions can be distilled into five core domains. These include drug discovery, personalized medicine, clinical trials, drug safety monitoring, and manufacturing and supply chain management. Table 1 provides a structured summary of these domains, outlining the specific AI contributions and the resulting benefits across the drug development lifecycle. This synthesis highlights how AI functions not only as a technological tool but also as a strategic enabler of efficiency, safety, and innovation in pharmaceutical practice.

Table 1. Key domains of AI contributions and benefits in pharmaceutical domains

| Area | AI contribution | Key benefit |
|-----------------------|--|---|
| Drug discovery | Uses molecular simulation and compound screening to identify potential drugs faster. | Speeds up research and reduces development costs. |
| Personalized medicine | Analyzes genomic and patient data to tailor treatments. | Creates more effective, individualized therapies. |

| | | |
|-----------------|--|---|
| Clinical trials | Optimizes trial design and patient recruitment using predictive models. | Cuts costs and accelerates approvals. |
| Drug safety | Detects adverse reactions through data monitoring and pattern recognition. | Improves drug safety and patient outcomes. |
| Manufacturing | Applies predictive analytics and digital twins to production processes. | Ensures reliable supply and efficient operations. |

15. Summary, conclusions and final thoughts

The integration of Artificial Intelligence (AI) into the pharmaceutical industry (PI) is fundamentally transforming various aspects of drug development, patient care, and operational efficiency. As AI technologies continue to evolve, their applications within the pharmaceutical sector are becoming increasingly sophisticated, offering unprecedented opportunities to enhance the drug discovery process, optimize clinical trials, and personalize treatment regimens. The impact of AI on drug discovery is profound. By utilizing machine learning algorithms and advanced data analytics, pharmaceutical companies can analyze vast datasets, including genomic, proteomic, and clinical data, to identify potential drug candidates more efficiently. This capability not only accelerates the identification of promising compounds but also enhances the likelihood of successful drug approvals. For instance, AI can predict the interactions between drug candidates and their targets, assess the pharmacokinetics and toxicity of compounds, and prioritize lead candidates for further development. As a result, the traditional timelines associated with drug discovery can be significantly reduced, leading to lower development costs and faster delivery of new therapies to the market. Moreover, AI is revolutionizing clinical trial design and execution. By leveraging predictive analytics, AI can optimize patient recruitment strategies, ensuring that clinical trials enroll the right participants based on genetic and demographic factors. This targeted approach not only increases the efficiency of trials but also improves the quality of data collected, ultimately enhancing the reliability of trial outcomes. Additionally, AI can monitor real-time data during trials, allowing for adaptive trial designs that can adjust protocols based on interim results. This flexibility is crucial in addressing the complexities of clinical research and can lead to more successful trial outcomes. In the realm of personalized medicine, AI plays a pivotal

role in tailoring treatments to individual patients. By analyzing patient-specific data, including genetic profiles and treatment responses, AI can help healthcare providers develop customized therapeutic strategies that maximize efficacy and minimize adverse effects. This personalized approach not only improves patient outcomes but also enhances adherence to treatment regimens, as patients are more likely to engage with therapies that are specifically designed for their unique health profiles. Furthermore, AI is streamlining pharmaceutical operations, from supply chain management to marketing strategies. By automating routine tasks and optimizing workflows, AI enables pharmaceutical companies to enhance productivity and reduce operational costs. For example, AI-driven analytics can forecast demand for medications, ensuring that supply chains are responsive and efficient. In marketing, AI can analyze patient data to identify trends and preferences, allowing companies to tailor their communications and outreach efforts effectively. Despite the significant advancements and potential of AI in the pharmaceutical industry, challenges remain. Issues related to data privacy, regulatory compliance, and the need for robust IT infrastructure must be addressed to fully realize the benefits of AI technologies. Additionally, the industry faces a talent gap, as the demand for skilled professionals who can navigate the complexities of AI and data science continues to grow. It is again stressed that AI is transforming the pharmaceutical industry by enhancing drug discovery, optimizing clinical trials, and personalizing medicine. Its impact extends to manufacturing, safety monitoring, and supply chain management. Below is four of the most powerful misconceptions business magnets have about the AI technology.

- ❖ AI, on its own, will deliver the bulk of the value to be created.
- ❖ AI can easily be plugged into existing data sets to unlock key insights.

- ❖ Selecting the right large language model (LLM) will be a key strategic differentiator.
- ❖ AI will instantly affect every part of the organization.

So, before pharma companies can seize the opportunities generative AI presents, they must step back and understand exactly what it can and cannot do—in other words, differentiate the reality of gen AI from the hype that has come to surround it. Further, to maximize the benefits of AI, stakeholders must focus on ethical considerations, regulatory compliance, and continuous innovation. Collaboration between AI experts, pharmaceutical companies, and regulatory bodies will be essential for achieving successful outcomes. In conclusion, the integration of AI into the pharmaceutical industry is not merely a trend but a transformative shift that is reshaping how drugs are discovered, developed, and delivered. As AI technologies continue to advance, they promise to enhance the efficiency and effectiveness of pharmaceutical operations, ultimately leading to better patient care and improved health outcomes. The future of the pharmaceutical industry will likely be defined by the successful implementation of AI-driven strategies that prioritize innovation, efficiency, and personalized medicine. Companies that embrace

this technological revolution will be well-positioned to lead the industry into a new era of healthcare, characterized by precision, speed, and improved patient engagement. Figure 6 is designed to summarize how AI helps pharmaceutical companies remain competitive by highlighting five key areas of impact:

1. **Improved drug discovery process** – AI accelerates identification of promising molecules and targets.
2. **More effective drug development and production** – AI optimizes workflows, reduces costs, and shortens timelines.
3. **Diagnostic assistance for personalized treatment** – AI supports clinicians in tailoring therapies to individual patients.
4. **Predicting epidemic outbreaks** – Machine learning models analyze large datasets to forecast public health trends.
5. **Enhanced sales and marketing** – AI helps pharma companies understand consumer behavior and market products more effectively.



Figure 6. Key applications of AI enabling pharmaceutical companies to stay competitive, including drug discovery, development and production, diagnostic support, epidemic prediction, and improved sales and marketing strategies.

To conclude, Artificial intelligence (AI) is reshaping the pharmaceutical landscape by enabling innovation across the entire value chain. From drug discovery and candidate generation (Figures 1–3) to

personalized medicine workflows (Figure 4) and industrial manufacturing optimization (Figure 5), AI provides the tools to accelerate research, improve efficiency, and ensure quality. Beyond the laboratory

and factory, AI also strengthens competitiveness by supporting diagnostics, epidemic prediction, and marketing strategies (Figure 6). Together with the structured synthesis presented in Table 1, these pictures demonstrate how AI delivers a seamless continuum of benefits—from molecular design to patient care and market impact. In the future, the continued integration of AI with emerging technologies such as quantum computing, advanced robotics, and real-world evidence platforms will further expand its role in pharmaceutical practice. By bridging scientific discovery, clinical application, and industrial scalability, AI is not only transforming current workflows but also laying the foundation for a more adaptive, data-driven, and patient-centered future in healthcare.

ACKNOWLEDGEMENT

The authors thank the Management of CDOE, MKU for encouraging to carryout this fundamental review work on AI in PI.

Conflict of Interest

The authors declare no conflicts of interest.

REFERENCES

1. National Center for Biotechnology Information. (2023). Artificial intelligence in drug discovery: Recent advances and future perspectives. *Frontiers in Pharmacology*. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385763/>
2. National Center for Biotechnology Information. (2020). Artificial intelligence in drug development: Applications and challenges. *Frontiers in Pharmacology*. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577280/>
3. McKinsey & Company. (2023). Generative AI in the pharmaceutical industry: Moving from hype to reality. Retrieved from <https://www.mckinsey.com/industries/life-sciences/our-insights/generative-ai-in-the-pharmaceutical-industry-moving-from-hype-to-reality>
4. *Acta Pharmaceutica Sinica B*. (2023). Artificial intelligence in pharmaceutical sciences. Retrieved from <https://www.sciencedirect.com/science/article/pii/S2095809923001649>
5. Petrie-Flom Center, Harvard Law School. (2023, March 20). How artificial intelligence is revolutionizing drug discovery. Retrieved from <https://blog.petrieflom.law.harvard.edu/2023/03/20/how-artificial-intelligence-is-revolutionizing-drug-discovery/>
6. *Trends in Pharmacological Sciences*. (2023). Artificial intelligence in drug discovery and development. Cell Press. Retrieved from <https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147%2823%2900137-2>
7. *Times of India*. (2024, April). Lowering drug development costs with AI. Retrieved from <https://timesofindia.indiatimes.com/technology/times-techies/lowering-drug-development-costs/articleshow/112073119.cms>
8. Gordon, C. (2024, February 23). Using AI to modernize drug development and lessons learned. *Forbes*. Retrieved from <https://www.forbes.com/sites/cindygordon/2024/02/23/using-ai-to-modernize-drug-development-and-lessons-learned/>
9. Vial. (2023). How can AI bring down the cost of drugs? Retrieved from <https://vial.com/blog/articles/how-can-ai-bring-down-the-cost-of-drugs/>
10. *Trends in Pharmacological Sciences*. (2023). Artificial intelligence in drug discovery and development. Cell Press. Retrieved from <https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147%2823%2900137-2>
11. *Annals of Medicine and Surgery*. (2023). Artificial intelligence in personalized medicine. Retrieved from https://journals.lww.com/annals-of-medicine-and-surgery/fulltext/2023/11000/artificial_intelligence_ai_in_personalized.94.aspx
12. Viseven. (2023). Artificial intelligence in pharma industry. Retrieved from <https://viseven.com/artificial-intelligence-in-pharma-industry/>
13. *Nature Reviews Bioengineering*. (2022). Artificial intelligence in drug discovery: Opportunities and challenges. Retrieved from <https://www.nature.com/articles/s41392-022-00994-0>

14. Globant. (2023). Target identification: Opportunities to leverage AI. Retrieved from <https://stayrelevant.globant.com/en/technology/data-ai/target-identification-opportunities-to-leverage-ai/>
15. Data Dynamics Inc. (2023). AI's masterstroke: Navigating and overcoming the eight biggest challenges in pharma. Retrieved from <https://www.datadynamicsinc.com/blog/ais-masterstroke-navigating-and-overcoming-the-eight-biggest-challenges-in-pharma/>
16. Spiceworks. (2023). Top challenges faced by pharma AI. Retrieved from <https://www.spiceworks.com/tech/artificial-intelligence/guest-article/top-challenges-faced-by-pharma-ai/>
17. Nature Medicine. (2023). Artificial intelligence in clinical trials. Retrieved from <https://www.nature.com/articles/s41591-023-02361-0>
18. Ideas2IT. (2023). AI in the pharmaceutical industry. Retrieved from <https://www.ideas2it.com/blogs/ai-pharmaceutical-industry>
19. BaseTwo AI. (2023). AI-enabled pharmaceutical manufacturing trends. Retrieved from <https://www.basetwo.ai/blogs/ai-enabled-pharmaceutical-manufacturing-trends>
20. Trends in Pharmacological Sciences. (2023). Artificial intelligence in pharmacology. Retrieved from <https://www.sciencedirect.com/science/article/pii/S0165614723001372>
21. LinkedIn Pulse. (2023). Personalized medicine: AI-driven genomic analysis and its impact on healthcare. Retrieved from <https://www.linkedin.com/pulse/personalized-medicine-ai-driven-genomic-analysis-its-impact-healthcare>
22. SciLife. (2023). AI pharma innovation challenges. Retrieved from <https://www.scilife.io/blog/ai-pharma-innovation-challenges>
23. National Center for Biotechnology Information. (2021). Artificial intelligence in pharmaceutical sciences. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877825/>
24. PubMed. (2023). Artificial intelligence in drug discovery and development. Retrieved from <https://pubmed.ncbi.nlm.nih.gov/37125780/>
25. Royal Society of Chemistry. (2024). Artificial intelligence in drug discovery. RSC Advances. Retrieved from <https://pubs.rsc.org/en/content/articlelanding/2024/ra/d3ra07322j>
26. Li, J., Jin, L., Wang, Z., Peng, Q., Wang, Y., Luo, J., Zhou, J., Cao, Y., Zhang, Y., Zhang, M., Qiu, Y., Hu, Q., Chen, L., Yu, X., Zhou, X., Li, Q., Zhou, S., Huang, S., Luo, D., Mao, X., Yu, Y., Yang, X., Pan, C., Li, H., Wang, J., & Liao, J. (2023). Towards precision medicine based on a continuous deep learning optimization and ensemble approach. *NPJ Digital Medicine*, 6(18). <https://doi.org/10.1038/s41746-023-00759-1>.

Cite: S. Anupriya, N. Anvarsha, P. Kalyani*, Artificial Intelligence (AI) In Pharmaceutical Industry (PI), *Int. J. Med. Pharm. Sci.*, 2026, 2 (5), 444-462. <https://doi.org/10.5281/zenodo.20130322>